The value of delayed phase enhanced imaging in malignant pleural mesothelioma

Patel, Ankur R.; Berger, Ian; Wileyto, E. Paul; Khalid, Umar; Torigian, Drew A.; Nachiappan, Arun C.; Barbosa, Eduardo J. Mortani; Gefter, Warren B.; Galperin-Aizenberg, Maya; Gupta, Neil; Simone, Charles B.; Haas, Andrew R.; Alley, Evan; Singhal, Sunil; Cengel, Keith A.; Katz, Sharyn I.

doi:10.21037/jtd.2017.07.86

Cited by 22 publications

(16 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the correlation we observed between tissue MVD and MSIG in MPM (r = 0.4258, p = 0.02, n = 28) appeared preserved, and indeed more powerful, when this analysis was confined to patients without macro-nodules (r = 0.6594, p = 0.003, n = 18). Furthermore, the 4.5 min SI peak observed here is concordant with a recent retrospective MRI study involving MPM patients, in which peak tumour enhancement occurred at 280 s post-gadolinium administration [ 32 ].…”

Section: Discussionsupporting

confidence: 90%

Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A recent study analysed contrast enhancement dynamics of MPM in MRI [15]. The results of the study demonstrate that optimal contrast enhancement of MPM in MRI is likely to occur 2.5-5 minutes following intravenous contrast agent administration.…”

Section: Discussionmentioning

confidence: 99%

“…However, correct phases were ensured by checking the images for established characteristics of arterial and portal venous phase. Evaluation of further scan delays apart from arterial and portal venous phase would be desirable especially in light of the abovementioned results of MR-imaging showing the best delay being > 2.5 minutes [15]. However, when studying the results of the MR trial in detail, there was not much of increasing intensity beyond 70 seconds scan delay.…”

Section: Discussionmentioning

confidence: 99%

Conspicuity of Malignant Pleural Mesothelioma in Contrast Enhanced MDCT – Arterial Phase or Late Phase?

Luerken

Thurn

Zeman

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To compare two different contrast phases intraindividually regarding conspicuity of MPM in chest MDCT. Methods: 28 patients with MPM were included in this retrospective study. For all patients, chest CT in standard arterial phase and abdominal CT in portal venous phase (scan delay ca. 70 s) was performed. First, subjective analysis of tumor conspicuity was done independently by two radiologists. Second, objective analysis was done by measuring Hounsfield units (HU) in tumor lesions and in the surrounding tissue in identical locations in both phases. Differences of absolute HUs in tumor lesions between phases and differences of contrast (HU in lesion – HU in surrounding tissue) between phases were determined. HU measurements were compared using paired t-test for related samples. Potential confounding effects by different technical and epidemiological parameters between phases were evaluated performing a multiple regression analysis.Results: Subjective analysis: In all 28 patients and for both readers conspicuity of MPM was better on late phase compared to arterial phase. Objective analysis: MPM showed a significantly higher absolute HU in late phase (75.4 vs 56.7 HU, p < 0.001). Contrast to surrounding tissue was also significantly higher in late phase (difference of contrast between phases 18.5 HU, SD 10.6 HU, p < 0.001). Multiple regression analysis revealed contrast phase and tube voltage to be the only significant independent predictors for tumor contrast.Conclusions: In contrast enhanced chest-MDCT for MPM late phase scanning seems to provide better conspicuity and higher contrast to surrounding tissue compared to standard arterial phase scans.

show abstract

“…Recent research has shown that the normally used time delay between contrast medium administration and start of image acquisition might not be sufficient to capture contrast phases optimal for MPM assessment. Patel et al 22,23 showed that enhancement of MPM at the conventional time delay of 40 to 60 seconds did not represent the maximal enhancement. In fact, the group estimated that the peak tumor enhancement occurs at 280 seconds following intravenous (IV) contrast injection (►Fig.…”

Section: Advanced Imaging In Malignant Pleural Mesothelioma Contrast Agent Kinetics In Mpmmentioning

confidence: 99%

Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

Martini

Frauenfelder

2021

Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Background The purpose of this article is to describe the various imaging techniques involved in detection, staging, and preoperative planning in malignant pleural mesothelioma (MPM) focusing on new imaging modalities. Methods For this purpose, first a brief summary of the etiology of MPM is given. Second, not only the commonly known, but also novel imaging modalities used in MPM will be discussed. Results A wide range of imaging methods, from conventional chest radiography, through computed tomography and hybrid imaging to radiomics and artificial intelligence, can be used to evaluate MPM. Conclusion Nowadays multimodality imaging is considered the cornerstone in MPM diagnosis and staging.

show abstract

The value of delayed phase enhanced imaging in malignant pleural mesothelioma

Abstract: Optimal MPM enhancement on MRI likely occurs at a time delay between 2.5-5 min following IV contrast administration. Further study of delayed phase enhancement of MPM with dynamic contrast enhanced MRI is warranted.

Cited by 22 publications

References 9 publications

Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy

Conspicuity of Malignant Pleural Mesothelioma in Contrast Enhanced MDCT – Arterial Phase or Late Phase?

Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

Contact Info

Product

Resources

About